The Warburg effect is the observation that cancer cells consume far more glucose than normal cells, even when plenty of oxygen is available. Instead of fully burning glucose for maximum energy the way healthy cells do, cancer cells convert most of it into lactate, a metabolic shortcut that produces far less energy per molecule of glucose. This seemingly wasteful behavior has puzzled scientists for a century, and understanding it has become central to how we detect and treat cancer.
How Normal Cells and Cancer Cells Use Glucose Differently
In a healthy cell with access to oxygen, glucose is broken down through a two-stage process. First, the cell splits glucose in the cytoplasm, generating a small amount of energy. Then the byproducts are shuttled into mitochondria, where they’re burned much more thoroughly. This full process yields about 30 molecules of ATP (the cell’s energy currency) per molecule of glucose.
Cancer cells largely skip that second stage. They stop at the first step, converting glucose into lactate right there in the cytoplasm and generating only 2 ATP molecules per glucose molecule. That’s 15 times less efficient. To compensate, cancer cells dramatically ramp up their glucose intake, pulling in far more sugar than surrounding tissue. Most of the carbon from that glucose gets excreted as lactate rather than used for anything.
Why Cancer Cells Choose an Inefficient Path
Otto Warburg first described this phenomenon in 1923. He eventually concluded that cancer cells behave this way because their mitochondria are damaged and can no longer burn fuel properly. That explanation turned out to be mostly wrong. Most cancer cells have functional mitochondria. The real reasons are more nuanced, and scientists are still working out the full picture.
One leading explanation is that the rapid, incomplete breakdown of glucose generates chemical building blocks that branching pathways can use to manufacture lipids, proteins, and the components of DNA and RNA. A cell that’s dividing quickly needs raw materials, not just energy, and glycolysis feeds several of those manufacturing pathways. However, this doesn’t fully explain the effect either. The majority of the biomass in rapidly dividing cells actually comes from amino acids, not glucose, and most of the glucose carbon still gets dumped out as lactate rather than channeled into building materials.
Another factor is speed. Glycolysis is fast. Even though it produces less energy per glucose molecule, it can generate ATP more quickly than the slower mitochondrial pathway. For a cell racing to divide, speed of energy production may matter more than efficiency. There’s also evidence that the lactate cancer cells excrete reshapes the surrounding tissue environment in ways that suppress immune responses and help tumors grow.
How PET Scans Exploit This Effect
The Warburg effect isn’t just a curiosity of cancer biology. It’s the basis for one of the most widely used cancer imaging tools: the PET scan. During a PET scan, you receive an injection of a radioactive glucose look-alike called 18F-FDG. This molecule enters cells the same way normal glucose does, carried by the same transport proteins on the cell surface. Once inside, it gets locked in place by the same enzymes that begin processing real glucose.
Because cancer cells are such aggressive glucose consumers, they accumulate far more of this tracer than normal tissue. The radioactive signal lights up on the scan, revealing where tumors are located, how large they are, and whether cancer has spread. The specific transport proteins that pull glucose into cells, GLUT1 and GLUT3, are highly overexpressed in many cancer types, which is what makes these scans so effective at spotting malignancies.
The Reverse Warburg Effect
In 2009, researchers proposed a twist on Warburg’s original idea. In some cancers, the tumor cells themselves aren’t the ones performing aerobic glycolysis. Instead, they coerce neighboring support cells, called cancer-associated fibroblasts, into doing it for them. These fibroblasts break glucose down into lactate and release it into the surrounding environment. The cancer cells then absorb that lactate and feed it into their own mitochondria as fuel.
This metabolic teamwork, called the reverse Warburg effect, describes a two-compartment system where the support cells do the glycolysis and the cancer cells do the efficient burning. Specialized lactate transporters called monocarboxylate transporters shuttle lactate back and forth between cell types. The lactate essentially becomes the primary fuel source for the cancer cells, whether or not oxygen is scarce. This cooperative metabolism helps explain why targeting glucose consumption in cancer cells alone sometimes fails to stop tumor growth.
Targeting Cancer Metabolism as Treatment
Because cancer cells are so dependent on altered metabolism, researchers have been developing drugs that attack various points in these metabolic pathways. The approaches are diverse. Some drugs block the lactate transporters that shuttle fuel between cells. AZD3965, for instance, is a first-in-class inhibitor of one of these transporters and has entered clinical trials. Others target glutaminase, the enzyme that processes the amino acid glutamine, which many cancers rely on heavily alongside glucose. Telaglenastat is a potent inhibitor of this enzyme currently being tested in patients.
Still other drugs go after the mitochondria directly or block amino acid transporters that cancer cells depend on. Some target mutant enzymes found only in certain cancer subtypes. Two such drugs, ivosidenib and enasidenib, have already received FDA approval for a form of leukemia driven by specific metabolic mutations. The broader goal is to starve cancer cells or disrupt the metabolic flexibility that lets them thrive, while leaving normal cells relatively unharmed.
The challenge is that cancer metabolism is not one single broken switch. Tumors can rewire their metabolic pathways, shift fuel sources, and recruit surrounding cells to help. Blocking one pathway often pushes cancer cells to rely on another. This is why most metabolic drugs in development are being tested in combination with immunotherapy or other treatments rather than as standalone therapies.